Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global ‘HS Uncovered’ Burden of Disease Survey

ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin disease. There is a need to evaluate how patients experience their disease. Objectives The HS Uncovered survey was conducted to understand patient activation, the patient journey and burden of disease. Methods HS Uncovered was a real‐world, quantitative, online survey completed by adults who self‐reported a diagnosis/suspected diagnosis of HS. The survey included patient‐reported outcome measures (PROMs) and non‐PROM‐related questions and was conducted between December 2022 to March 2023 in six countries (US, UK, Germany, France, ltaly, Spain). PROMs included the Patient Activation Measure (PAM13; primary endpoint), Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment (WPAI) and Hospital Anxiety and Depression Scale (HADS) tools (Spain excluded from PROM analyses). Results Overall, 656 participants were included ( N = 505, diagnosed HS; N = 151, suspected HS). Of 425 diagnosed participants, 66% reported high (level 3/4) PAM13 scores. A very large (DLQI score 11–20) and extremely large (DLQI score 21–30) effect of HS on QoL was reported by 41% and 28% of participants, respectively. A very large to extremely large effect of HS on QoL (DLQI score 11–30) was reported by 67% and 73% of patients with level 3 and 4 PAM13 scores, respectively. Overall, 53% and 29% of diagnosed participants reported abnormal anxiety and depression, respectively. The percentage of work impairment due to HS in employed diagnosed participants ( N = 302) was 52%. Of diagnosed females, 52% considered HS a concern for family planning. Overall ( N = 656), 58% of participants considered pain relief the most important treatment feature. Conclusions Despite participants having high activation levels, HS had a negative impact on QoL, mental health, work and activity. There is an unmet need for effective treatments that provide sustained pain reduction and improve work productivity in HS.

Authors

Institutions

Publication Details

Journal
JEADV Clinical Practice
Published
2025-05-30
DOI
https://doi.org/10.1002/jvc2.70071
Primary Topic
Hidradenitis Suppurativa and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global ‘HS Uncovered’ Burden of Disease Survey

Eva Vilarrasa, Amit Garg, Ivette Alarcón, Georgios Kokolakis et al.
1 links
JEADV Clinical Practice
Hidradenitis Suppurativa and Treatments
article

Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global ‘HS Uncovered’ Burden of Disease Survey

Eva Vilarrasa, Amit Garg, Ivette Alarcón, Georgios Kokolakis, Craig Richardson, Barry M. McGrath, Philippe Guillem, Aikaterini Mamareli, Mei Go, Gillian Newbold
article en

Abstract

ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, painful inflammatory skin disease. There is a need to evaluate how patients experience their disease. Objectives The HS Uncovered survey was conducted to understand patient activation, the patient journey and burden of disease. Methods HS Uncovered was a real‐world, quantitative, online survey completed by adults who self‐reported a diagnosis/suspected diagnosis of HS. The survey included patient‐reported outcome measures (PROMs) and non‐PROM‐related questions and was conducted between December 2022 to March 2023 in six countries (US, UK, Germany, France, ltaly, Spain). PROMs included the Patient Activation Measure (PAM13; primary endpoint), Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment (WPAI) and Hospital Anxiety and Depression Scale (HADS) tools (Spain excluded from PROM analyses). Results Overall, 656 participants were included ( N = 505, diagnosed HS; N = 151, suspected HS). Of 425 diagnosed participants, 66% reported high (level 3/4) PAM13 scores. A very large (DLQI score 11–20) and extremely large (DLQI score 21–30) effect of HS on QoL was reported by 41% and 28% of participants, respectively. A very large to extremely large effect of HS on QoL (DLQI score 11–30) was reported by 67% and 73% of patients with level 3 and 4 PAM13 scores, respectively. Overall, 53% and 29% of diagnosed participants reported abnormal anxiety and depression, respectively. The percentage of work impairment due to HS in employed diagnosed participants ( N = 302) was 52%. Of diagnosed females, 52% considered HS a concern for family planning. Overall ( N = 656), 58% of participants considered pain relief the most important treatment feature. Conclusions Despite participants having high activation levels, HS had a negative impact on QoL, mental health, work and activity. There is an unmet need for effective treatments that provide sustained pain reduction and improve work productivity in HS.

JEADV Clinical PracticeVol. 4(4)
Novartis (Switzerland) (CH), Hospital de Sant Pau (ES), IQVIA (United Kingdom) (GB), Humboldt-Universität zu Berlin (DE), North Shore Diabetes and Endocrine Associates (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Novartis, Sanofi, Biogen, Celgene, Mylan, Incyte, Insmed, IC Design Education Center, Galderma, Basilea Pharmaceutica, Sun Pharma, LEO Pharma, Novartis Pharma, Actelion Pharmaceuticals, Cilag
Openalex Percentile: Top 77%
Hidradenitis Suppurativa and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.